Epidemiological factors, such as vitamin D, Epstein-Barr virus, smoking and adolescent obesity, are associated with multiple sclerosis (MS) susceptibility and may be involved in MS aetiology. There is also evidence of gene-environment interactions. Both validated predictive biomarkers and gene-expression data will play a crucial role in future diagnosis of MS and prognosis facilitating early treatment and improving management. Understanding the mode of action of disease-modifying therapies (DMTs) should also enhance MS management by identifying the best treatment for different stages of the disease course. Magnetic resonance imaging (MRI) plays a significant role in both diagnosis and monitoring of patients and is likely to become part of the daily MS practice using standardised protocols and software to increase reproducibility. A future goal of MS treatment is to facilitate neuron repair and remyelination. In this respect, animal models of remyelination could be useful in identifying potential therapies. Diagnosis of radiological syndrome is now simpler, but its management is controversial and it does not always convert to MS. In addition, treatment for progressive MS is problematic as current DMTs are indicated only for relapsingremitting MS. Symptomatic treatment is a neglected aspect of MS management, which is often the main concern of both patients and neurologists. Neurologists need to collaborate in trials and consider repurposed drugs that could provide treatment for these symptoms.
longitudinal studies with excess rates ranging from 1.3 to 1.7 for heavy long-term smokers compared with never smokers. Smoking increases both the incidence of MS and the risk of secondary progression and increases the risk of MS both in current and past smokers with duration and intensity independently affecting MS susceptibility. 4, 5 It may also influence the MS disease course.
Higher body mass index (BMI) (>27 kg/m 2 ) before age 20 is associated with increased risk of MS with a twofold risk in women obese at age 10 and 20, although the mechanism is unclear. to shift the focus from treating MS to primary prevention for which it will be crucial to understand and then target the pathways that lead to immune dysregulation of MS. 
Predictive Markers in Multiple Sclerosis
A biomarker can be defined as 'a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathological processes or pharmacologic responses to a therapeutic intervention'. 8 The identification of validated biomarkers would be of Thus EAE has helped in the development of immunotherapies that effect the inflammatory phase of MS. However, it is also well-known that many therapies that worked in this model have not shown to be beneficial in the human disease. is necessary for their recruitment to the demyelinated plaque. 25 Endogenous guidance cues that control the migration of OPC during development include class 3 semaphorins (Sema 3A-attractant and 3F-repellant) and netrin 1 genes. 26 Over-expression of Sema 3F gene increases both OPC recruitment (not due to proliferation) and also the remyelination rate. 27 By contrast, overexpression of netrin prevents OPC recruitment and delays remyelination. Thus, early recruitment of OPCs after demyelination promotes remyelination, whereas preventing this recruitment decreases remyelination rate. The leucine-rich repeat and Ig domain containing 1 gene (Lingo 1) inhibits oligodendrocyte maturation and therefore an anti-lingo monoclonal antibody has been evaluated in a completed phase I trial and currently two phase II trials in RRMS and ON are ongoing. 28, 29 Many unsolved questions concerning remyelination remain, including the type of endogenous repair strategy (promoting recruitment of maturation) and which patients are suitable for treatment. A further limitation is the lack of a surrogate marker for remyelination.
Panel Discussion
It is uncertain if DMTs completely suppress inflammation and the resulting outcome could be problematical since inflammation is necessary for remyelination, but the exact mechanism is not fully understood. High-dose cytotoxic drugs suppress inflammation but not in the brain. The compartmentalisation 30 of inflammation that occurs in the later stages of MS is seen in the Tylers animal model, which could therefore be used to study therapies. Interestingly, microbes in the gut of EAE mice appear to have a role in suppressing inflammation and this could be true for MS but studies are needed to verify this effect. In 2014 a revised definition of PMS was proposed incorporating PPMS (progressive accumulation of disability from onset) and SPMS (progressive accumulation of disability after an initial relapsing course).
Mode of Action of Immunomodulatory Drugs in Multiple Sclerosis
The course can be:
• Active with progression (PPMS);
• Not active without progression;
• Active without progression; and
• Not active with progression. 34 The different pathologies associated with MS suggest different therapeutic targets. Altered peripheral immunity to myelin could be due to broken tolerance and may be restored by DNA vaccines, or may be due to defective immunoregulation where peptide, cytokine or cellbased therapies could re-establish it. Many DMTs have been approved for RRMS but it is uncertain if they are effective for inflammatory tissue injury in the CNS, although some can enter the CNS. Macroglial and microglial activation in PMS are involved in continuing cortical demyelination, a process that has also been identified in early MS.
Furthermore, subpial demyelination also occurs and may reflect compartmentalised inflammation. 39 Vigorous remyelination occurs at times in MS, but almost always fails. Remyelination is unequivocally neuroprotective since chronic axonal degeneration is entirely absent from remyelinated shadow plaques. 40 After demyelination sodium influx occurs, which reverses the sodium-calcium exchange leading to accumulation of intra-axonal calcium and activation of injury cascades. 41 The proof-of-principle that PMS may be treatable has been shown in a phase II trial assessing the effect of high-dose simvastatin on brain atrophy and disability in SPMS. The mean annualised atrophy rate was significantly lower in treated patients (43 % reduction versus placebo; p=0.003). 42 A phase III trial is now justified to confirm this promising result.
Main Driving Mechanisms of Different Phases of Multiple Sclerosis
Both which is a major mechanism of demyelination and neurodegeneration in MS lesions. A similar degree of oxidative injury was not seen in other inflammatory brain diseases. 43 The predominant changes in expression of genes were for axonal and dendritic plasticity and myelin regeneration.
Mitochondrial injury in MS is driven by inflammation in which oxidative
bursts accumulate with disease duration leading to energy deficiency.
Furthermore, injured mitochondria are an additional source of reactive oxygen species.
The pathophysiology of PMS has consequences for therapy. Since there are similar disease mechanisms between RMS and PMS, early effective treatment should delay onset of progression. However, drugs that are effective in PMS must act within the CNS and treatment should target both inflammation and neurodegeneration. A recent study demonstrated that the MTR is: higher in the outer cord layer than cord white matter, lower in patient groups compared with controls (controls>CIS>RRMS>SPMS=PPMS), abnormal in CIS and RRMS patients and independently correlated with cord atrophy. 51 Spinal cord atrophy can be measured by 3D T1 MRI and correlates with EDSS -the mean rate of cord area loss is 1 % per year. However, there is no consistent correlation between T2 lesion load and disability.
Impact of Magnetic Resonance Imaging Techniques on Clinical Practice
A more accurate measure of cord lesion can be obtained with a combination of 3D-T2 and 3D-PSIR (T1) axial images. 52 In a multivariate regression model cord lesion load and cord atrophy have been shown to independently contribute to EDSS (R 2 = 0.56). 53 
Future Magnetic Resonance Imaging-based Techniques that should be Part of Daily Multiple Sclerosis Practice
In order to monitor inflammatory activity it is likely that a subjective count of new lesions will be necessary using MRI techniques. This will entail using image subtraction from consecutive timepoints with automated software accounting for intensity normalisation inhomogeneity correction and image co-registration. 54 The utility of monitoring lesion activity (inflammation) is exemplified by a 20-year study in CIS patients of disability and T2 MRI lesions. The estimated rate of lesion growth over 20 years was 0.8 cm 3 /year in those with a RRMS course and 2.89 cm 3 / year in those who developed SPMS. 55 Results from another study in RRMS patients indicated that the number of new T2 lesions at 1 year predicted the 5-year EDSS score. 56 
The Changing Spectrum of Neuromyelitis Optica
Diagnostic criteria for neuromyelitis optica (NMO) and transverse myelitis were first developed in 2006, but subsequently a number of observations have suggested that they should be revised, including:
• The discovery that NMO-IgG can be reliably recognised earlier;
• Recurrent myelitis or recurrent ON occur;
• Brain lesions may occur -as the presenting manifestations and can be highly suggestive or diagnostic; and 
Stem Cells in Neurological Disorders
The multifocal nature of MS complicates cellular therapy and puts emphasis on both the donor cell origin and the route of cell transplantation.
Considerable progress had been made in the development of NSCs. The origin of microglial cells was uncertain but recently it was discovered that in mice they develop in the yolk sac and infiltrate the early forebrain of embryos via the blood circulation and therefore their appearance in the CNS precedes the onset of neurogenesis. 64 Transplanted stem cells work therapeutically through cell replacement and also via the bystander effect. NPCs and other types of stem cell exert neuroprotective effects by secreting trophic factors and immunomodulatory molecules.
These foster endogenous precursors to promote remyelination and to directly and indirectly rescue damaged axons/neurons and also recapitulate physiological non-neurogenic homeostatic functions exerted by endogenous NPCs.
A number of important issues, however, remain to be addressed, for example, the optimum way to tightly control and regulate the various therapeutic stem cell-mediated effects in vivo. These include:
• The differentiation state of the cells (stem or precursor).
• Whether the cells should be injected in the acute or chronic phase.
• The number of cells in single or multiple injections.
• The injection route (homotopic or heterotopic).
Symptomatic Treatment in Multiple Sclerosis
The 67 Bladder dysfunction is also well controlled both with and without drugs and a simple algorithm has been developed. 68 By contrast, fatigue is poorly managed with no strong evidence for successful drug treatment but aerobic exercise, physiotherapy, yoga and progressive resistance training having a weak effect. Unfortunately the numerous drugs that can be used to relieve symptoms often have side effects that worsen the symptoms being treated.
Neurologists need to collaborate to develop clinical trials and establish better quantitative measures to address patients' unmet needs. In addition, funding agencies should urgently allocate specific directed funding for individual symptom relief.
Panel Discussion
The consensus was that treatment should be stopped when SPMS starts but in the US it is restricted when a certain age is reached. A biomarker to inform when it is safe to stop treatment would be valuable. The treatment rationale for MS is debatable because as many as 90 % of lesions could be asymptomatic. The participants at this meeting agreed, however, that early treatment is beneficial, although it is important to choose the best medication and aim to personalise treatment. As funds for drugs treatments are limited in most countries, there is an increasing need for safe and effective therapies in MS that are, above all, less expensive.
Future MS Days meetings are planned with the aim of continuing to help clinicians to keep up-to-date with the latest developments and advocate the most effective treatments and best practice in MS management.
Nation-specific Treatment Approaches in Multiple Sclerosis
Based on the natural history of MS, early aggressive treatment should be initiated in RRMS to suppress disease activity since preventing relapses and development of underlying progression should reduce later disability. Evidence that earlier treatment potentially gives better outcomes has been accumulated with all DMTs from CIS and long-term follow-up studies. 69 An assessment of how countries approach treatment of RRMS has recently been completed. In order to achieve more uniform access to effective treatment a number of factors should be considered, including the efficacy of the healthcare system, the advocacy and knowledge of providers and the role of regulators, lay organisations and pharma. Responses to severn questions were collected from 16 countries. MS prevalence varied from >200/100,000 in Denmark and
Germany to <10/100,000 (China, India, Japan and Korea) and in all countries a drug regulatory authority oversaw the availability of MSspecific drugs. However, there was variation regarding the time when 
Challenges and Difficulties in the Diagnosis and Treatment of Multiple Sclerosis in Turkey
The findings of a 36-question survey to compare the opinion of 318 neurologists (285 general versus 33 MS experts) in 22 cities in Turkey on MS diagnosis, management, pregnancy issues and timing/interpretation of MRI scans were discussed. The survey results indicated that:
• In clinically stable patients fewer general neurologists refer patients for a follow-up MRI scan than MS experts whereas 6-month MRI referral rates are higher in general neurologists. MS experts also tend to follow patients more frequently.
• General neurologists were more likely to depend on radiologist's reports, whereas MS experts interpret MRIs themselves.
• MS experts consider presence of black holes and brain atrophy in progressing patients to be more important variables than general neurologists.
• General neurologists switch DMTs faster and treat more RIS patients and would not consider brain atrophy or low vitamin D levels factors for treatment change.
Often the radiologist did not wait long enough to obtain a good GD contrast and their reports generally contained errors. On switching, if a new lesion appeared after 1 year of treatment, it was generally agreed that it is best to maintain treatment and monitor the patient closely. The time needed to assess treatment response varied from 3 to 12 months and a patient should be followed up 1 month after treatment initiation. 
73-76
The diagnosis of RIS requires the presence of incidentally identified CNS white matter anomalies meeting the following MRI criteria: 77, 78 • Ovoid, well-circumscribed, homogeneous foci with/without corpus callosum involvement.
• T2-hyperintensities (>3 mm) fulfilling three of four Barkof criteria for dissemination in space.
• CNS anomalies not consistent with a vascular pattern.
• No historical accounts of remitting clinical symptoms.
• MRI anomalies not due to direct physiological effects of substances (recreational drugs, toxic exposure).
• Exclusion of MRI phenotypes suggestive of leukoaraiosis or extensive white matter pathology lacking involvement of the corpus callosum.
• MRI anomalies not better accounted for by another disease process.
An Radiologically Isolated Syndrome Consortium (RISC) study evaluated the 5-year risk of the development of the first symptomatic demyelinating event in 451 RIS subjects. Of these, 83 % had positive spinal cord MRI and 10 % developed PPMS, which mirrors populationbased studies. The main risk factors were spinal cord lesions, age <37 and male gender. 35 However, standardised studies are required to improve diagnostic criteria and risk estimates. Management/ treatment of RIS is controversial. Three strategies have been proposed: wait (no follow-up, but patients advised to seek healthcare if symptoms occur); planned clinical and radiological follow-up; and treat with DMT (but potential benefit unproven). Surveys suggest that periodic evaluation is the most common approach but off-label treatment is increasing.■
